TrialJournal of Crohn's & colitis2024

The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.

Bram Verstockt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.